Extra HIV drug helps severely ill patients rebuild immune defenses
NCT ID NCT00302822
First seen Apr 11, 2026 · Last updated May 14, 2026 · Updated 2 times
Summary
This study tested whether adding an extra HIV drug called enfuvirtide to standard therapy for 6 months helps people with very advanced HIV infection. The 195 participants had dangerously low CD4 counts (a measure of immune health) and had never taken HIV drugs before. The goal was to see if more patients could reach a safer CD4 level (above 200) after 24 weeks of treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Service des Maladies Infectieuses A Hôpital Bichat-Claude Bernard
Paris, 75018, France
Conditions
Explore the condition pages connected to this study.